ASCENT

Serial Number 90133732
688

Registration Progress

Application Filed
Aug 24, 2020
Under Examination
May 13, 2025
Approved for Publication
Mar 18, 2025
Published for Opposition
Mar 18, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Nov 13, 2025 105 days

Trademark Image

ASCENT

Basic Information

Serial Number
90133732
Filing Date
August 24, 2020
Published for Opposition
March 18, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
May 13, 2025
Application
Pending
Classes
042

Rights Holder

RegenxBio Inc.

03
Address
9804 Medical Center Drive
Rockville, MD 20850

Ownership History

RegenxBio Inc.

Original Applicant
03
Rockville, MD

RegenxBio Inc.

Owner at Publication
03
Rockville, MD

Legal Representation

Attorney
William R. Samuels

USPTO Deadlines

Next Deadline
105 days remaining
NOA E-Mailed - SOU Required
Due Date
November 13, 2025
Extension Available
Until May 13, 2026

Application History

43 events
Date Code Type Description Documents
Jun 9, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 13, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 18, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 20, 2025 EXPT T EXPARTE APPEAL TERMINATED Loading...
Feb 20, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 11, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 11, 2025 ALIE A ASSIGNED TO LIE Loading...
Jan 10, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 6, 2024 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Dec 6, 2024 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
Dec 6, 2024 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Dec 6, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Jul 12, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jul 12, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Jun 6, 2024 CNFR R FINAL REFUSAL WRITTEN Loading...
Jun 6, 2024 GNFR O FINAL REFUSAL E-MAILED Loading...
Jun 6, 2024 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Apr 18, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 16, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 16, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 22, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 22, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 22, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 19, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 19, 2024 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 19, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 12, 2023 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Mar 20, 2023 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Feb 8, 2023 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Jun 22, 2022 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Dec 22, 2021 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Jun 22, 2021 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Jun 21, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jun 21, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 21, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Dec 19, 2020 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Dec 19, 2020 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Dec 19, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 19, 2020 CNSL R SUSPENSION LETTER WRITTEN Loading...
Sep 26, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 27, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Medical and scientific research, namely, conducting clinical trials for others, all the above for gene therapy, namely for use in the treatment of wet age-related macular degeneration (AMD) using subretinal delivery

Classification

International Classes
042